Related Experiment Video
Updated: Nov 20, 2025

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
Published on: May 16, 2022
Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target
Jason Charles Ray1,2, Mahima Kapoor3,2, Richard J Stark3,2
1Neurology, Alfred Health, Melbourne, Victoria, Australia j.ray@alfred.org.au.
Abstract:
Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Direct-Acting Cholinergic Agonists: Therapeutic Uses

